William Blair resumed coverage of Insulet with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2026 | Outperform | William Blair | |
| 4/24/2026 | $220.00 | Buy → Neutral | Rothschild & Co Redburn |
| 4/7/2026 | $230.00 | Buy → Neutral | Citigroup |
| 1/27/2026 | $294.00 | Hold | TD Cowen |
| 1/12/2026 | $274.00 | Overweight → Equal Weight | Barclays |
| 12/16/2025 | $370.00 | Outperform | Evercore ISI |
| 11/19/2025 | $400.00 | Neutral → Buy | UBS |
| 10/21/2025 | $370.00 | Buy | Stifel |
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
William Blair resumed coverage of Insulet with a rating of Outperform
Rothschild & Co Redburn downgraded Insulet from Buy to Neutral and set a new price target of $220.00
Citigroup downgraded Insulet from Buy to Neutral and set a new price target of $230.00
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans. "At Insulet, we believe
Enhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps users improve time in range and stay in Automated Mode longer Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor in U.S., giving users more choice in how they manage their diabetes New features are designed to improve outcomes, reduce diabetes burden, and unlock barriers to AID technology to meet the needs of people with diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery
Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipo
SD - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330524787/en/ "We have a significant growth opportunity in front of us, driven by strong clinical outcomes
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in
Raises Full Year Total Company Revenue Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4 million, rose 36.9%, or 33.0% in constant currency U.S. Omnipod revenue of $515.6 million, increased 28.3% International Omnipod revenue of $242.9 million, increased 59.4
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929
Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) and Full Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency) Represents 10th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2025. Fourth Quarter Financial Highlights: Revenue of $783.8 million, up 31.2%, or 29.0% in constant currency, and exceeded the high end of the Company's guidance range of 25% to 28% in constant currency Total Omnipod
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)